Ironwood Q2 Earnings Beat Estimates, Revenues Lag, 2026 View Raised
IRWD tops Q2 earnings estimates, misses on revenues and lifts its 2026 outlook as strong Linzess demand drives year-over-year growth.
Zacks Investment Research8/7/2026Positive
IRWD
Ironwood Pharmaceuticals IncNASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Key Statistics
Market Cap
$720.45M
P/E Ratio
5.45
EPS
$0.80
Beta
0.21
52W High
$5.78
52W Low
$1.01
50-Day MA
$3.97
200-Day MA
$3.79
Dividend Yield
—
Profit Margin
33.40%
Forward P/E
12.33
PEG Ratio
-0.26
About Ironwood Pharmaceuticals Inc
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. The company is headquartered in Boston, Massachusetts.
Fundamentals
| Revenue (TTM) | $389.32M |
| Gross Profit (TTM) | $300.62M |
| EBITDA | $238.10M |
| Operating Margin | 70.20% |
| Return on Equity | -575.00% |
| Return on Assets | 47.00% |
| Revenue/Share (TTM) | $2.39 |
| Book Value | $-1.32 |
| Price-to-Book | 2.59 |
| Price-to-Sales (TTM) | 1.85 |
| EV/Revenue | 2.641 |
| EV/EBITDA | 4.25 |
| Quarterly Earnings Growth (YoY) | 125.70% |
| Quarterly Revenue Growth (YoY) | 32.60% |
| Shares Outstanding | $165.24M |
| Float | $136.77M |
| % Insiders | 3.23% |
| % Institutions | 98.48% |
Historical Volatility
HV 10-Day
69.22%
HV 20-Day
77.61%
HV 30-Day
72.85%
HV 60-Day
65.08%
HV Rank
17.5%
Volatility is currently contracting
Analyst Ratings
Consensus ($6.10 target)
1
Strong Buy1
Buy2
HoldLatest News
Ironwood Pharmaceuticals, Inc. (IRWD) Q2 2026 Earnings Call Transcript
Ironwood Pharmaceuticals, Inc. (IRWD) Q2 2026 Earnings Call Transcript
Seeking Alpha8/6/2026Neutral
Ironwood Pharmaceuticals Q2 Earnings Call Highlights
Ironwood Pharmaceuticals NASDAQ: IRWD reported second-quarter results marked by higher LINZESS sales, the start of enrollment in its confirmatory Phase III study of apraglutide, and repayment of its convertible notes, prompting the company to raise its full-year 2026 financial outlook.
MarketBeat8/6/2026Neutral
Ironwood Pharmaceuticals (IRWD) Q2 Earnings Top Estimates
Ironwood Pharmaceuticals (IRWD) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.26 per share. This compares to earnings of $0.14 per share a year ago.
Zacks Investment Research8/6/2026Positive
Buy The Dip: 2 Top Undervalued Stocks Averaging 394% Forward EPS Growth
Despite the recent market selloff, earnings expectations continue to rise: The S&P 500's Q2 EPS is projected to grow by 37.9%, while net profit margins could reach a 15-year high. Buying the dip can present opportunities for investors. When fear fades, markets have historically returned to fundamentals. Using Seeking Alpha's Quant Tools, I found two Strong Buy stocks, beaten down in the past month, offering both solid growth and value.
Seeking Alpha7/31/2026Positive
Ironwood Pharmaceuticals: One Trial Stands Between Bargain And Bust
Ironwood Pharmaceuticals trades at a 40% discount to its risk-adjusted sum-of-the-parts valuation, anchored by LINZESS and apraglutide. I assign a 'Buy' rating on IRWD and a $6.3 price target, citing a margin of safety, but I also warn of a binary risk tied to apraglutide's pivotal trial. LINZESS faces a patent cliff in 2029, with revenue projected to decay rapidly following the entry of generic products.
Seeking Alpha7/30/2026Negative
Here's Why Ironwood Pharmaceuticals (IRWD) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks Investment Research7/15/2026Positive
Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced the retirement of Chief Medical Officer and Head of Research and Drug Development Dr. Michael Shetzline and the appointment of Dr. Jeffrey Silber as his successor. Dr. Silber will oversee Research and Drug Development, Regulatory Affairs and Medical Affairs reporting.
Business Wire7/14/2026Neutral
4 Defensive Stocks to Take Refuge in as Tech Sell-off Continues
COLL, IRWD, AMTB and DUK stand out as defensive stock picks as investors rotate from AI-driven tech amid the ongoing sell-off and seek safer sectors.
Zacks Investment Research7/8/2026Neutral
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook article.
Zacks Investment Research6/26/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on IRWD and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 8/18/2026